Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies (Q38249099)

1 September 2017

1 reference

title

Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies (English)

1 reference

1 September 2017

W Du

1

1 reference

1 September 2017

O Elemento

series ordinal

2

1 reference

1 September 2017

language of work or name

English

0 references

publication date

15 September 2014

1 reference

1 September 2017

1 reference

1 September 2017

34

1 reference

1 September 2017

25

1 reference

1 September 2017

3215-3225

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2014.291

1 September 2017

0 references

cites work

Genomic instability--an evolving hallmark of cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Epigenetic reprogramming in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Microenvironmental regulation of tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Clonal evolution in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Clinical development success rates for investigational drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Comprehensive molecular characterization of clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Stromal gene expression predicts clinical outcome in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Network quantification of EGFR signaling unveils potential for targeted combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Interplay between Epigenetics and Genetics in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

DNA methylation in cancer: too much, but also too little

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Global histone modification patterns predict risk of prostate cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Comprehensive identification of mutational cancer driver genes across 12 tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Passenger deletions generate therapeutic vulnerabilities in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Impact of deleterious passenger mutations on cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The clonal evolution of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

21 January 2018

p53 mutations in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Genome-wide mutational signatures of aristolochic acid and its application as a screening tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Intra-tumour heterogeneity: a looking glass for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Genetic variegation of clonal architecture and propagating cells in leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Turning ecology and evolution against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Sequencing technologies - the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Landscape of genomic alterations in cervical carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Punctuated evolution of prostate cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Increased methylation variation in epigenetic domains across cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Transcriptomic landscape of breast cancers through mRNA sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Novel insights into breast cancer genetic variance through RNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Transcriptome sequencing to detect gene fusions in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

RNA sequencing of cancer reveals novel splicing alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Tumour evolution inferred by single-cell sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Single-cell dissection of transcriptional heterogeneity in human colon tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Algorithms for detecting significantly mutated pathways in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Heterogeneity of tumor-induced gene expression changes in the human metabolic network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Emerging landscape of oncogenic signatures across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Development of a prognostic model for breast cancer survival in an open challenge environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Exploiting evolution to treat drug resistance: combination therapy and the double bind

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Feedback regulation of lymphocyte signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The distinctive nature of HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Global, in vivo, and site-specific phosphorylation dynamics in signaling networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Reverse-phase protein lysate microarrays for cell signaling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The microenvironment of the tumour-host interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Macrophage regulation of tumor responses to anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Tumour-educated macrophages promote tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

TGF-beta signaling in tumor suppression and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

In silico experimentation of glioma microenvironment development and anti-tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Tumor-immune interaction, surgical treatment, and cancer recurrence in a mathematical model of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Predicting and controlling the reactivity of immune cell populations against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Model for in vivo progression of tumors based on co-evolving cell population and vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The molecular pathology of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Methodological and practical challenges for personalized cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

The quest to overcome resistance to EGFR-targeted therapies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Personalized oncology through integrative high-throughput sequencing: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Genome-wide identification of post-translational modulators of transcription factor activity in human B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

A whole-cell computational model predicts phenotype from genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Genetic Interactions in Cancer Progression and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Melanoma genome sequencing reveals frequent PREX2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Application of molecular technologies for phosphoproteomic analysis of clinical samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

A community effort to assess and improve drug sensitivity prediction algorithms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.291

Optical imaging of tumor microenvironment

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25220419

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25220419

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2014.291

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference